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Abstract
Background: The aim of this trial was to compare the effectiveness of two generations of progressive lenses for
presbyopia.
Methods: A multicenter cross-over randomized controlled trial performed in a primary care setting (5 optical
dispensaries) was planned. Two categories of progressive lenses were compared: 1) a new-generation lens (i.e.,
VARILUX PANAMIC ORMA CRIZAL), which is expensive but a supposed improvement in comfort, and 2) an
older-generation lens (i.e., VARILUX CONFORT ORMA CRIZAL), which is less expensive and is considered the
reference lens. Patients were randomized to wear one generation of progressive lens for 4 weeks, then cross
over to wear the other lens for 4 weeks, without knowing the sequence of lenses.
Inclusion criteria were 1) age 43–60 years; 2) outpatients already wearing progressive lenses and referred to an
optician ophthalmologist for optical correction prescription within the last 6 months; 3) receiving a correction of
≤3 dioptres in cases of associated myopia, hyperopia or astigmatism; 4) understanding and speaking French and
able to answer a questionnaire; and 5) giving written consent to participate in the study.
The primary outcome was patient preference for one progressive lens at week 8. Secondary outcomes were
subjective measures of bifocal visual performance, including a) near visual acuity, b) visual field, c) kinetic visual
skills, d) visual adaptability, e) visual comfort, and f) rapidity of adaptation.
Results: 127 patients were randomized to one of the lens groups. Two patients withdrew prematurely; 98.4%
and 97.6% patients who wore the new versus older lenses, respectively, wore their progressive lenses every day
during the 4-week period 1 and period 2. The number of participants in each of 5 centres varied from 16 (12.6%)
to 35 (27.6%).
57.9% patients preferred the new-generation lenses, 36.5% the older-generation lenses, and 5.6% had no
preference (p = 0.01). The two groups did not differ in any of the measures of bifocal visual performance except
near visual acuity.
Conclusion:  Patients with presbyopia had slightly higher preference for the new-generation than older-
generation lens, with no difference in lens groups for most of the visual outcomes assessed.
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Background
Presbyopia is a chronic disorder involving changes in
accommodation of the eye and causing difficulty in near
vision. It is a process of age-related progressive loss of
accommodative amplitude [1,2]. Presbyopia is associated
with worse health-related quality of life in terms of vision
[3-5]. Correction of presbyopia includes bifocal or trifocal
lenses, progressive lenses, bifocal or progressive contact
lenses and surgery [6,7]. Because of continuous improve-
ment in design of progressive lenses, these have become
the treatment of choice for many practitioners [8,9]. Since
the first progressive lenses, several types of progressive
lenses with varying costs have been proposed. Essilor is
the French leader in manufacturing progressive lenses and
has developed a succession of lenses, including VARILUX
CONFORT and VARILUX PANAMIC. Although VARILUX
PANAMIC is more expensive, its effectiveness has never
rigorously been compared to the older-generation VAR-
ILUX CONFORT.
We aimed to perform a randomized controlled trial com-
paring the effectiveness of two progressive lenses for pres-
byopia – a new-generation lens (VARILUX PANAMIC
ORMA CRIZAL) and an older-generation progressive lens
(VARILUX CONFORT ORMA CRIZAL)-in terms of patient
preference and subjective measures of bifocal visual per-
formance.
Methods
Design
A multicenter cross-over randomized controlled trial was
designed. This design removes patient variation and
allowed us to estimate treatment effect with greater preci-
sion: individual response to treatment A was compared
with the same subject's response to treatment B. This
design was particularly fitting because presbyopia is a
chronic disease with short-term outcomes, and the treat-
ment does not interact with the underlying disorder. Fur-
thermore, patients included were already wearing
progressive lenses for presbyopia. They were referred to an
optical dispensary with an optical correction prescription.
Consequently, the carry-over effect is probably negligible
[10].
The trial was approved by the institutional review board
of Cochin Hospital, Paris. Informed consent was obtained
from all participants, and all clinical investigations were
conducted according to the principles of the Declaration
of Helsinki. This study report followed the guidelines of
the CONSORT Statement and its extension to reports of
nonpharmacological treatments [11-13].
Participants
Optical dispensaries participating in this trial were
selected from partners of the healthcare insurance compa-
nies Santéclair and Groupama in France. Both companies
were involved in the funding of the trial. Five optical dis-
pensaries based in Paris or nearby agreed to participate.
They were committed to inform patients, check selection
criteria, obtain informed consent, include patients,
administer the allocated progressive lenses, and collect
information.
To be included in the trial, patients had to be 1) 43 to 60
years old; 2) outpatients already wearing progressive
lenses for presbyopia and consulting an optical dispen-
sary with an optical correction prescription within the last
6 months; 3) receiving correction of = 3 dioptres in cases
of associated myopia, hyperopia or astigmatism; 4)
understanding and speaking French and able to answer a
questionnaire; and 5) giving a written consent to partici-
pate with the study. Exclusion criteria were 1) first pre-
scription of progressive lenses for presbyopia, 2)
associated strabism, 3) associated amblyopia, 4) receiving
orthoptics therapy, 5) associated anisometropia > 1.5
dioptres, and 6) receiving treatment for diabetes.
Patient screening was organized by the healthcare insur-
ance company Santéclair which has a consumer panel of
specifically trained counsellors. Consumers could contact
the panel for advice and to be referred to one of the optical
dispensary partners of the insurance companies. All
patients contacting the panel and meeting inclusion crite-
ria were invited to participate. They were referred for
inclusion if they agreed to use a participating optical dis-
pensary. A standardized text was used to check patient eli-
gibility. The text is available upon request.
Sequence allocation generation
Patients were randomly assigned to 2 treatment
sequences: 1) use of the older-generation progressive lens
(i.e., VARILUX CONFORT ORMA CRIZAL) for 4 weeks
followed by the new-generation lens (i.e., VARILUX
PANAMIC ORMA CRIZAL) for 4 weeks; or 2) use of the
new-generation lens (i.e., VARILUX PANAMIC ORMA
CRIZAL) for 4 weeks followed by the older-generation
lens (i.e., VARILUX CONFORT ORMA CRIZAL) for 4
weeks. Randomisation was stratified on optical dispensa-
ries. A randomisation code was generated by a statistician
at the Department of Epidemiology, Biostatistics and
Clinical Research, Bichat Hospital, who was not involved
in the conduct and analysis of the study. A computer ran-
dom-number generator was used to select random per-
muted blocks, with block lengths of 4, 8, and 10.
Allocation concealment
To ensure allocation concealment, the random list was
sent to an independent central laboratory in charge of
assembling all the equipment for 5 optical dispensaries.
The list was not provided to the optical dispensaries or toTrials 2008, 9:54 http://www.trialsjournal.com/content/9/1/54
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any sponsors. After obtaining informed consent from the
patient, the optical dispensary asked for a patient's inclu-
sion number by faxing an inclusion form to Santéclair. For
the purpose of the study, Santéclair was also in charge of
allocating patients' inclusion numbers by order of fax
arrival. With this patient's inclusion number, the optical
dispensary ordered from the central laboratory two sets of
equipment for patients. A set of equipment consisted of
one pair of progressive lenses and one spectacle frame.
Then the central laboratory sent the equipment to the
optical dispensary and indicated with an appropriate
blinded label the sequence of use of each set.
Intervention
We compared two categories of progressive lenses: 1) the
new-generation lens (i.e., VARILUX PANAMIC ORMA
CRIZAL), which is expensive but a supposed improve-
ment in comfort, and 2) an older-generation progressive
lens (i.e., VARILUX CONFORT ORMA CRIZAL), which is
less expensive. Both lenses were indexed 1.5 and had the
same anti-reflection coating treatment. These properties
were chosen according to usual optical corrections pro-
posed to patients. Patients had to choose among a limited
range of spectacle frames (10 styles). When participating
in the trial, patients did not have to pay for the spectacle
frame and the progressive lenses. Patients were allowed to
keep the preferred equipment at the end of the trial as in
incentive for taking part in the trial.
Blinding
In this trial, the primary and secondary outcomes were
patient-reported outcomes. Because outcomes were sub-
jective and the outcome assessor was the patient, blinding
of the patients was particularly important. To ensure ade-
quate blinding, the equipment provided to the patients
was strictly similar: same spectacle frame, colour, shape,
and weight. The two sets of equipment were assembled in
the central lab on the same day by the same technician.
The only variable to be tested was therefore the generation
of the progressive lenses. All progressive lenses were pro-
vided by the same manufacturer (i.e., Essilor). However,
all lenses manufactured by Essilor are engraved with a tiny
mark, so people aware of the mark could guess the
assigned lens. To ensure the success of blinding, patients
were not informed of this mark, and opticians were com-
mitted to not checking the treatment administered and
not informing patients of the distinction.
Outcomes
To assess outcomes, patients were clinically evaluated by
their opticians during visits at baseline and at weeks 4 and
8. The primary outcome was evaluated at the final visit
(i.e., week 8), and secondary outcomes were assessed dur-
ing the follow-up period (i.e., weeks 4 and 8). The primary
outcome was patient preference for a progressive lens
based on period of wear. Patients had to indicate the
period they preferred on a scale of -5 to 5 (i.e., -5 to -1:
preference for period 1; 0: no preference; 1 to 5: preference
for period 2). Secondary outcomes were subjective meas-
ures of various areas of bifocal visual performance. These
were measured on a scale of 0–10 (i.e., 0, extremely bad;
10, excellent) and included assessment of a) near visual
acuity (i.e., < 40 cm: read a book), b) distance visual acu-
ity (i.e., > 5 m: watch a movie in a cinema, look at an
advertising slot or a road sign), c) intermediate visual acu-
ity (i.e., 40 cm to 5 m: computer work, look at prices
through a shop window or people around a table), d) glo-
bal visual acuity, e) distance visual field (i.e., look at the
other side of the road and focus on the sharp area around
something you stare at), f) near visual field (i.e., stare at a
letter in a book and evaluate the sharp area around this
letter), g) kinetic visual skills when the person is moving
but the environment is still (i.e., walk and stare at prices
through a shop window); h) kinetic visual skills when the
person is still but the environment is moving (i.e., driv-
ing), i) visual adaptability, and j) visual comfort. Finally,
we assessed rapidity of visual adaptation to progressive
lenses on an 8-point Likert scale (immediately, in few
hours, 1 day, 2–3 days, 1 week, 2 weeks, more than 2
weeks, never). We considered that visual adaptation was
faster when reported as immediate or in few hours.
Adverse events
All adverse events were systematically collected. We found
no expected adverse events. Severity was classified accord-
ing to the World Health Organization classification. All
severe adverse events were systematically reported by the
optical dispensaries. The relation between intervention
and adverse events was assessed by the optician.
Sample size
The primary outcome was patient preference for a progres-
sive lens based on period of wear: new-generation or
older-generation lens or no preference. We calculated
sample size on the basis of the hypothesis that 40%
patients would prefer the new-generation lens, 40%
would have no preference and 20% would prefer the
older-generation lens. If we consider only patients
expressing a preference, we would compare patients pre-
ferring the new-generation lens (i.e., 66.7% = 40/
(40+20)) to a theoretical 50%. With an alpha risk of 5%
and a power of 80%, the estimated sample size was 68
patients. Considering that about 40% patients would not
provide informative data (i.e., would have no preference)
and a rate of lost to follow-up of about 15%, we aimed for
a sample of 130 patients.
Statistical methods
Statistical analysis was performed by a blinded statistician
(CR) at the Department of Epidemiology, BiostatisticsTrials 2008, 9:54 http://www.trialsjournal.com/content/9/1/54
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and Clinical Research, Bichat Hospital. Analyses were con-
ducted according to a pre-specified plan based on the
principle of intent-to-treat (i.e., data for all participants
were analysed in the group participants were assigned to,
regardless of whether they completed the intervention).
Descriptive statistics (mean and standard deviation [SD],
extreme values) were used for continuous variables. Cate-
gorical variables were described with frequencies and per-
centages. The primary outcome was evaluated by a 2-
tailed Prescott's test (i.e., takes into account the effect of
period and patients with no preference). Secondary out-
comes were evaluated by an F test: a linear mixed-effects
model, with the secondary outcome as the dependent var-
iable and fixed effects for sequence, study group, and
period, with patients within sequence as a random effect.
Data analyses involved use of SAS 9.1 (SAS Institute Inc,
Cary, NC, USA).
Results
Participants
Patients were screened and enrolled from February to
November 2006. The flow of participants through the trial
is reported in figure 1. Baseline characteristics of patients
are summarized in table 1. The number of participants in
each of the 5 centres varied from 16 (12.6%) to 35
(27.6%). In period 1, one patient allocated to the new-
generation lens first (i.e., VARILUX PANAMIC ORMA
CRIZAL) withdrew prematurely, and 98.4% patients wore
Table 1: Patient characteristics at baseline
Total
N = 127
New-generation 
lens first
N = 63
Older-generation 
lens first
N = 64
Patient characteristics
-Sex (male/female) [n (%)] 49/78 (38.6/61.4) 21/42 (33.3/66.7) 28/36 (43.7/56.3)
-Age (years) [mean (SD)] 53.0 (5.1) 52.1 (4.9) 53.9 (5.1)
-Time since the first prescription for progressive lens for presbyopia (years) 
[mean (SD)]
5.7 (4.5) 5.5 (4.8) 6.0 (4.1)
-Time since patients wore their equipment before having a new prescription for 
progressive 
lens for presbyopia (years) [mean (SD)]
2.3 (2.0) 2.1 (1.9) 2.5 (2.0)
Reason for prescription
-Correction modification [n (%)] 90 (70.9) 39 (61.9) 51 (79.7)
-Lack of comfort [n (%)] 22 (17.3) 12 (19.0) 10 (15.6)
-Aesthetics [n (%)] 16 (12.6) 9 (14.3) 7 (10.9)
Visual defect
-Myopia [n (%)] 51 (40.5) 27 (43.5) 24 (37.5)
-Hyperopia [n (%)] 75 (59.5) 35 (56.4) 40 (62.5)
-Astigmatism [n (%)] 89 (70.1) 46 (73.0) 43 (67.2)
Previous correction
-Anti-reflection coated (yes) [n (%)] 94 (74.6) 51 (82.3) 43 (67.2)
-Sphere sign RE (+/-) [n (%)] 67/48 (58.3/41.7) 31/24 (56.4/43.6) 36/24 (60.0/40.0)
-Sphere sign LE (+/-) [n (%)] 71/47 (60.2/39.8) 33/25 (56.9/43.1) 38/22 (63.3/36.7)
-Sphere RE [mean (SD)] 1.0 (0.7) 0.9 (0.8) 1.0 (0.7)
-Sphere LE [mean (SD)] 1.0 (0.7) 1.0 (0.8) 0.9 (0.6)
-Cylinder RE [mean (SD)] 0.6 (0.3) 0.6 (0.3) 0.5 (0.3)
-Cylinder LE [mean (SD)] 0.6 (0.3) 0.6 (0.3) 0.6 (0.3)
-Axis RE [mean (SD)] 95.7 (59.0) 83.4 (57.5) 108.7 (58.5)
-Axis LE [mean (SD)] 92.3 (58.7) 99.1 (52.5) 85.3 (64.6)
-Addition RE [mean (SD)] 1.9 (0.6) 1.9 (0.7) 1.9 (0.5)
-Addition LE [mean (SD)] 1.9 (0.6) 1.9 (0.7) 1.9 (0.5)
New correction
-Sphere sign RE (+/-) [n (%)] 70/50 (58.3/41.7) 30/26 (53.6/46.4) 40/24 (62.5/37.5)
-Sphere sign LE (+/-) [n (%)] 73/50 (59.3/40.7) 35/26 (57.4/42.6) 38/24 (61.3/38.7)
-Sphere RE [mean (SD)] 1.0 (0.7) 1.0 (0.8) 1.1 (0.7)
-Sphere LE [mean (SD)] 1.0 (0.8) 1.1 (0.8) 1.0 (0.7)
-Cylinder RE [mean (SD)] 0.6 (0.4) 0.6 (0.4) 0.6 (0.5)
-Cylinder LE [mean (SD)] 0.7 (0.4) 0.7 (0.4) 0.6 (0.5)
-Axis RE [mean (SD)] 101.2 (58.4) 91.7 (57.5) 112.6 (58.2)
-Axis LE [mean (SD)] 95.6 (58.6) 97.6 (53.5) 93.7 (63.7)
-Addition RE [mean (SD)] 2.1 (0.5) 2.1 (0.5) 2.2 (0.5)
-Addition LE [mean (SD)] 2.1 (0.5) 2.1 (0.5) 2.2 (0.5)
RE: Right eye, LE: Left eyeTrials 2008, 9:54 http://www.trialsjournal.com/content/9/1/54
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their progressive lenses every day during the 4 weeks. In
period 2, one patient allocated to the older-generation
lens first (i.e., VARILUX CONFORT ORMA CRIZAL) with-
drew prematurely, and 97.6% patients wore their progres-
sive lenses every day during the 4 weeks.
Outcomes
At the end of the follow-up, 57.9% patients preferred the
new generation of progressive lens (i.e., VARILUX
PANAMIC ORMA CRIZAL; 50.0% of patients allocated to
the new-generation lens first and 65.6% of patients allo-
cated to the older-generation lens first), 36.5% preferred
the old-generation lens (i.e., VARILUX CONFORT ORMA
CRIZAL; 45.2% of patients allocated to the new-genera-
tion lens first and 28.1% of patients allocated to the older-
generation lens first) and 5.6% had no preference (4.8%
of patients allocated to the new-generation lens first and
6.2% of patients allocated to the older-generation lens
first) (p = 0.01). Bifocal visual performance did not differ
between the two groups, except for near visual acuity,
Flow diagram of patients through the trial Figure 1
Flow diagram of patients through the trial.
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which was better with the new-generation lens (i.e., VAR-
ILUX PANAMIC ORMA CRIZAL) (table 2). Figure 2
presents the mean scores for bifocal visual performance in
periods 1 and 2. Table 3 describes the rapidity of visual
adaptation with the older- and new-generation of lenses.
The adaptation was faster with the new-generation lens
(i.e., VARILUX PANAMIC ORMA CRIZAL).
We did not detect any statistically significant carry-over
effect for secondary outcomes.
Harm
No adverse events were reported during the study.
Discussion
We compared the effectiveness of two progressive lenses
prescribed for presbyopia in terms of patient preference
for a lens and subjective measures of bifocal visual per-
formance. To our knowledge, no study has rigorously
assessed the effectiveness of the new generation of pro-
gressive lens (VARILUX PANAMIC ORMA CRIZAL) versus
the older-generation lens (VARILUX CONFORT ORMA
CRIZAL). For the primary outcome, approximately half of
the patients preferred the new-generation lens and about
one third preferred the older-generation lens. Although
the period of wear seemed to influence patients' prefer-
ence (i.e., patients' preference for the new-generation lens
tended to be more pronounced when patients wore the
old generation first), the effect was not statistically signif-
icant. The two groups did not differ in most of the second-
ary outcomes assessed (e.g., distance, intermediate, and
global visual acuity; distance and near visual field; kinetic
visual skills; visual comfort; visual adaptability) but did
differ in near visual acuity, which was better with the new-
generation lens. However, the difference was small (0.6
on a 0–10 numeric scale) and the clinical relevance of this
difference is probably questionable.
Nijkamp et al. previously showed that quality of corrected
near vision acuity was a predictor of patient satisfaction
[14]. As well, lenses must fit properly. Adaptation to the
lenses and comfort are important expectations for patients
Table 2: Secondary outcomes
Bifocal visual performance, 0–10 scale Period 1
N = 63
Mean (SD)
Period 2
N = 64
Mean (SD)
P value*
Near visual acuity 0.02
-New-generation lens first 8.1 (2.3) 7.8 (2.2)
-Older-generation lens first 7.9 (1.9) 8.5 (1.6)
Distance visual acuity 0.38
-New-generation lens first 8.3 (2.0) 8.2 (1.7)
-Older-generation lens first 8.2 (1.6) 8.4 (1.8)
Intermediate visual acuity 0.46
-New-generation lens first 7.4 (2.6) 7.4 (2.3)
-Older-generation lens first 7.7 (2.0) 8.1 (2.2)
Global visual acuity 0.35
-New-generation lens first 7.7 (2.0) 7.6 (2.0)
-Older-generation lens first 7.9 (1.5) 8.1 (2.1)
Distance visual field 0.60
-New-generation lens first 7.6 (2.2) 7.7 (2.1)
-Older-generation lens first 7.8 (1.6) 8.1 (1.9)
Near visual field 0.16
-New-generation lens first 7.3 (2.4) 7.2 (2.2)
-Older-generation lens first 7.0 (2.0) 7.7 (2.1)
Kinetic visual skills when the person is moving but the environment is still 0.20
-New-generation lens first 7.5 (2.2) 7.5 (2.2)
-Older-generation lens first 7.5 (1.8) 8.1 (2.0)
Kinetic visual skills when the person is still but the environment is moving 0.22
-New-generation lens first 7.5 (2.2) 7.6 (2.1)
-Older-generation lens first 7.7 (1.7) 8.2 (1.8)
Visual adaptability 0.25
-New-generation lens first 7.6 (2.8) 7.7 (2.3)
-Older-generation lens first 7.5 (1.9) 8.2 (2.2)
Visual comfort 0.69
-New-generation lens first 7.6 (2.4) 7.6 (2.1)
-Older-generation lens first 7.8 (1.5) 8.0 (2.4)
* Study group effect tested by F test in the framework of a linear mixed-effect modelTrials 2008, 9:54 http://www.trialsjournal.com/content/9/1/54
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Table 3: Rapidity of adaptation to progressive lenses in periods 1 and 2. 
Sequence Faster adaptation for the lens 
of period 1 
(immediate or few hours)
No difference Faster adaptation for the lens 
of 
period 2 
(immediate or few hours)
TOTAL
NN N N
New-generation lens then older-
generation lens
14 35 12 61
Older-generation lens then new-
generation lens
53 9 1 9 6 3
TOTAL 19 74 31 124
Patients had fast adaptation if they answered that the adaptation was immediate or in a few hours. Patients were considered as having a long 
adaptation if they answered that the adaptation was more than few hours.
Prescott 2-tailed test: p = 0.0315
Mean scores of bifocal visual performance (0–10 numeric scale) Figure 2
Mean scores of bifocal visual performance (0–10 numeric scale).
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wearing lenses [15]. We found a tendency, although not
significant, for an effect of period of wear, as shown in fig-
ure 2. In fact at the end of period 1, subjective assessment
of the bifocal visual performance of lenses was similar for
both groups, but subjective assessment was higher for
wearers of the new-generation lens in period 2. Further,
adaptation was significantly faster for the new-generation
lens than with the older-generation lens.
Assessment of progressive lenses in presbyopia is a chal-
lenge because presbyopia is frequent and is related to ele-
vated medical cost. In the past 4 years, only two
randomised controlled trials have assessed interventions
for presbyopia [14,16]. Methodological difficulties may
explain this insufficiency in assessing interventions for
presbyopia. Assessment of nonpharmacological interven-
tions such as progressive lenses in presbyopia is difficult.
Respect for scientific standards is important to guarantee
the quality of assessment. The planning and conduct of
this trial followed the guidelines established for nonphar-
macological treatments [12,13,17]., but we encountered
methodological difficulties. First, the choice of primary
outcome was not easy. The primary outcome was a
patient-reported outcome. We chose patient preference
because comfort is of high importance for patients wear-
ing progressive lenses. Second, blinding of patients was
particularly important because outcomes were subjective
and the outcome assessor was the patient. To guarantee
the success of blinding, progressive lenses allocated were
strictly similar but were all engraved with a tiny mark dis-
tinguishing the new versus older lenses. Although patients
were not informed of this distinction, the presence of this
mark could be considered a limit to adequate blinding.
Conclusion
Patients showed a tendency to prefer the new generation
of progressive lens for presbyopia. Approximately half the
patients preferred the new-generation lens (i.e., VARILUX
PANAMIC ORMA CRIZAL) and only one-third the older-
generation lens (i.e., VARILUX CONFORT ORMA CRI-
ZAL).
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